title: [The clinical importance of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in the 5-fluoropyrimidine-based therapy of metastatic colorectal tumours].
abstract: The authors investigated the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in 101 metastatic colorectal cancer patients treated with 5-fluoropyrimidine-based therapy and in 196 healthy individuals by PCR-RFLP method. There was no significant difference in genotype distribution of patients and healthy controls, and between subgroups investigated according to clinical parameters (age, gender, tumor location, grade and treatment type). However, after a 3-30 (median 18.5) months follow-up the survival of patients with T allele proved to be better than that of patients with wild type (CC) genotype (p=0.036). In case of CT and TT genotypes the survival of patients receiving only first line therapy was significantly shorter than that of patients receiving more lines of treatment (p=0.015). Determination of MTHFR C677T polymorphism has prognostic value in case of patients with metastatic colorectal cancer receiving 5-fluoropyrimidine-based therapy, and may help in designing the individual (group) tailored therapy.
authors.affiliation: Országos Onkológiai Intézet, Budapest 1122, Hungary. budai@oncol.hu
authors.forename: Barna
authors.initials: B
authors.lastname: Budai
authors.forename: Erika
authors.initials: E
authors.lastname: Hitre
authors.forename: Vilmos
authors.initials: V
authors.lastname: Adleff
authors.forename: Ferenc
authors.initials: F
authors.lastname: Czeglédi
authors.forename: Fruzsina
authors.initials: F
authors.lastname: Gyergyay
authors.forename: István
authors.initials: I
authors.lastname: Láng
authors.forename: Judit
authors.initials: J
authors.lastname: Kralovánszky
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016022:Case-Control Studies; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D003596:Cytosine; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D011237:Predictive Value of Tests; D011379:Prognosis; D011743:Pyrimidines / Q000008:administration & dosage*; D016019:Survival Analysis; D013941:Thymine
chemical_list: D011743:Pyrimidines; C029269:5-fluoropyrimidine; D003596:Cytosine; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D013941:Thymine